Champions Oncology Reports Decline in Profitability for Third Quarter, Net Loss of $279,000

Champions Oncology, Inc. reported its financial results for the third quarter and nine months ended January 31, 2026, revealing a decline in profitability compared to the previous fiscal period. The company generated oncology revenue of $16.6 million for the three months ended January 31, 2026, a decrease of 2.8% from $17.0 million in the same period last year. For the nine months, revenue increased slightly to $45.6 million from $44.6 million, marking a 2.2% rise. However, the company recorded a net loss of $279,000 for the quarter, a significant drop from a net income of $4.5 million in the prior year, and a net loss of $508,000 for the nine months compared to a profit of $6.5 million in the same period last year.

The financial performance was impacted by rising costs, particularly in the cost of oncology revenue, which surged by 33.5% to $8.8 million for the quarter, primarily due to increased outsourced laboratory services. Research and development expenses also rose significantly, increasing by 32.1% for the quarter and 43.3% for the nine months, reflecting higher costs associated with outsourced laboratory services and increased compensation expenses. General and administrative expenses rose by 24.1% for the quarter and 25.0% for the nine months, driven by higher compensation and IT infrastructure costs.

Operationally, Champions Oncology continues to focus on its TumorGraft Technology Platform, which provides personalized cancer care through patient-derived xenograft models. The company has four operating subsidiaries, but none reported revenue during the reported periods. The total number of shares outstanding as of January 31, 2026, was 13,886,826, with an accumulated deficit of approximately $80.4 million. The company’s cash position decreased to $7.1 million from $9.8 million at the end of the previous fiscal year, reflecting cash used in operations.

Looking ahead, Champions Oncology expressed confidence in its ability to fund operations through at least March 2027, despite the negative working capital of $492,000. The company plans to continue investing in its research and development initiatives and expanding its commercial capabilities. However, management acknowledged the potential need for additional capital, emphasizing that there is no assurance of successfully raising funds on acceptable terms. The company remains focused on leveraging its technology platforms to enhance drug discovery and development processes while navigating the challenges posed by market conditions.